About Xiran
Xiran Health is dedicated to the R&D and manufacturing of ophthalmic minimally invasive surgical equipment, providing one-stop ophthalmic diagnosis and treatment equipment and consumable solutions. Our mission: Innovation in healthcare, safeguarding vision.
Company Overview
Hangzhou Xiran Medical Device Technology Co., Ltd. was established in Beijing in October 2020. Currently, it has a clean plant of over 2,000 square meters in Jiaxing and an R&D site of over 1,000 square meters in Zhuhai. To date, it has received several hundred million yuan in investment from well-known top domestic investment institutions such as Legend Capital, Taiyu, and Bilinstar.
Corporate Mission
It is an ophthalmic product company dedicated to the R&D, production, sales, and surgical training of ophthalmic surgery equipment and consumables, aiming to provide one-stop services related to surgery for ophthalmic surgeons.
Founding Team
The founding team consists of engineers who have been deeply involved in the field of ophthalmic surgical products for nearly forty years, as well as senior surgical trainers and ophthalmology experts, dedicated to developing a full product line of ophthalmic surgery, covering cataract surgery, vitrectomy, eye trauma surgery, and other fields. Additionally, professional basic and advanced surgical training are provided to young surgeons to shorten their learning curve.
Core Products
The company's core products include cataract phacoemulsification systems, vitreous cutting surgical systems, ultrasound vitrectomy and laser vitrectomy systems, fiber-based ophthalmic optical coherence tomography systems, etc.
Qualifications & Achievements
The company has been approved for one Class III, six Class II, and four Class I registration certificates domestically. Among them, the marketed ophthalmic surgical equipment (combined phacoemulsification and vitrectomy machine) is China's first domestically developed combined phacoemulsification and vitrectomy machine equipment. It has been approved for multiple invention and utility model patents, is safe, efficient, and has independent patents. Clinical trial enrollment for vitrectomy has been carried out at the top five ophthalmic hospitals nationwide, receiving unanimous praise from top domestic ophthalmic experts.
Industry Breakthroughs
Its approval means that Chinese companies have finally achieved key technical breakthroughs in high-end ophthalmic surgical equipment, filling the gap in domestic combined phacoemulsification and vitrectomy machine equipment. The ophthalmic surgical kit is the only approved vitrectomy and combined kit in the country, filling the domestic gap in this product field, effectively addressing domestic shortage substitution, urgent clinical needs, and other issues. Additionally, dozens of products are being submitted or prepared for registration. The laser vitrectomy and fiber-based ophthalmic optical coherence tomography systems under development are both global first launches, filling domestic gaps in their respective fields.
Investors
R&D Bases
嘉兴
2000+ sqm clean plant
珠海
1000+ sqm R&D site
Looking Forward to Working with You
If you are interested in our products or services, please feel free to contact us